Ep. 182 GLP-1 Drugs - One Thing They Don't Reduce
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Ep. 182 GLP-1 Drugs - One Thing They Don't Reduce
-
Lu par :
-
De :
GLP-1 drugs like Ozempic and Wegovy have revolutionized the management of diabetes and obesity. Millions of Americans are experimenting with them. Celebrities like Oprah are sharing their experiences. Duke Sanford School of Public Policy faculty member Jonathan Zhang is an economist who works on health policy, health economics and public finance. His research shows that GLP-1 drugs live up to their promise in everyday medical care. But the study also finds that, at least in the short run, they do not reduce overall health care spending.
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment